<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04768062</url>
  </required_header>
  <id_info>
    <org_study_id>NS-065/NCNP-01-302</org_study_id>
    <nct_id>NCT04768062</nct_id>
  </id_info>
  <brief_title>Study to Assess the Safety and Efficacy of Viltolarsen in Ambulant Boys With DMD (RACER53-X)</brief_title>
  <official_title>A Phase 3, Multi-center, Open-label Extension Study to Assess the Safety and Efficacy of Viltolarsen in Ambulant Boys With Duchenne Muscular Dystrophy (DMD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NS Pharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nippon Shinyaku Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>NS Pharma, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 3, multi-center, open-label extension study in ambulant boys with DMD who&#xD;
      have completed the 48-week treatment period of either viltolarsen or placebo in Study&#xD;
      NS-065/NCNP-01-301.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This Phase 3 study is a multi-center, open-label extension study in ambulant boys with DMD&#xD;
      who have completed the 48-week treatment period of either viltolarsen or placebo in Study&#xD;
      NS-065/NCNP-01-301. Patients will receive viltolarsen administered IV at weekly doses of 80&#xD;
      mg/kg.&#xD;
&#xD;
      Study NS-065/NCNP-01-302 will be comprised of a 96-week treatment period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">April 13, 2021</start_date>
  <completion_date type="Anticipated">June 2026</completion_date>
  <primary_completion_date type="Anticipated">June 2026</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment related Adverse Events as assessed by CTCAE v4.03</measure>
    <time_frame>baseline to up to 96 weeks of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Stand Test (TTSTAND)</measure>
    <time_frame>baseline to 96 weeks of treatment</time_frame>
    <description>Change in Time to Stand</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Run/Walk 10 Meters Test (TTRW)</measure>
    <time_frame>baseline to 96 weeks of treatment</time_frame>
    <description>Change in Time to Run/Walk 10 meters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Six-minute Walk Test (6MWT)</measure>
    <time_frame>baseline to 96 weeks of treatment</time_frame>
    <description>Change in Six-minute Walk</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>North Star Ambulatory Assessment (NSAA)</measure>
    <time_frame>baseline to 96 weeks of treatment</time_frame>
    <description>Change in North Star Ambulatory Assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Climb 4 Stairs Test (TTCLIMB)</measure>
    <time_frame>baseline to 96 weeks of treatment</time_frame>
    <description>Change in Time to Climb 4 Stairs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle Strength Measured by Hand-Held Dynamometer</measure>
    <time_frame>baseline to 96 weeks of treatment</time_frame>
    <description>Change in Muscle Strength Measured by Hand-Held Dynamometer</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">74</enrollment>
  <condition>Duchenne Muscular Dystrophy</condition>
  <arm_group>
    <arm_group_label>Viltolarsen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients amenable to exon 53 skipping will receive viltolarsen intravenous (IV) infusions, weekly, at 80 mg/kg for up to 96 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Viltolarsen</intervention_name>
    <description>Received during weekly intravenous infusions</description>
    <arm_group_label>Viltolarsen</arm_group_label>
    <other_name>NS-065/NCNP-01</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient has completed the NS-065/NCNP-01-301 study;&#xD;
&#xD;
          2. Patient's parent(s) or legal guardian(s) has (have) provided written informed consent&#xD;
             and Health Insurance Portability and Accountability Act authorization, where&#xD;
             applicable, prior to any study-related procedures; patients will be asked to give&#xD;
             written or verbal assent according to local requirements;&#xD;
&#xD;
          3. Patient and parent(s)/guardian(s) are willing and able to comply with scheduled&#xD;
             visits, investigational product (IP) administration plan, and study procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient had an adverse event in Study NS-065/NCNP-01-301 that, in the opinion of the&#xD;
             investigator and/or the sponsor, precludes safe use of viltolarsen for the patient in&#xD;
             this study;&#xD;
&#xD;
          2. Patient had a treatment which was made for the purpose of dystrophin or&#xD;
             dystrophin-related protein induction after completion of Study NS-065/NCNP-01-301;&#xD;
&#xD;
          3. Patient took any other investigational drug(s) during or after completion of Study&#xD;
             NS-065/NCNP-01-301;&#xD;
&#xD;
          4. Patient is judged by the investigator and/or the sponsor not to be appropriate to&#xD;
             participate in the extension study for any reason.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Fondazione Policlinico Universitario A. Gemelli - Universita Cattolica del Sacro Cuore</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Center of Neurology and Psychiatry</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pusan National University Yangsan Hospital</name>
      <address>
        <city>Pusan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leids Universitair Medisch Centrum</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christchurch Clinical Studies Trust</name>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Zealand Clinical Research Ltd.</name>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Russian National Research Medical University</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Saint Petersburg State Paediatric Medical University&quot; based at Consultative and Diagnostic Centre</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tomsk National Research Medical Center of Russian Academy of Sciences</name>
      <address>
        <city>Tomsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Sant Joan de Deu</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yeditepe University Kosuyolu Hospital</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Turkey</country>
  </location_countries>
  <link>
    <url>https://clinicaltrials.gov/ct2/show/NCT04060199</url>
    <description>Study to Assess the Efficacy and Safety of Viltolarsen in Ambulant Boys With DMD (RACER53)</description>
  </link>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>February 19, 2021</study_first_submitted>
  <study_first_submitted_qc>February 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 24, 2021</study_first_posted>
  <last_update_submitted>November 12, 2021</last_update_submitted>
  <last_update_submitted_qc>November 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Muscular Dystrophy, Duchenne</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

